上海谊众公告，预计2025年度实现归属于母公司所有者的净利润为6000万元到7000万元，与上年同期相 比，增长760.18%到903.54%。公司核心产品注射用紫杉醇聚合物胶束于2025年正式纳入国家医保目 录，在市场准入与用药人数上大幅提高，带动了公司全年营收与利润相较于2024年显著增长。 ...

Group 1 - The core point of the article is that Kaiyin Technology (688687.SH) has voluntarily withdrawn its application for the listing of its hepatitis B drug, leading to a significant drop in its stock price by 11.78% on January 21, making it the largest decline in the A-share market that morning [1] - The company received a termination notice from the National Medical Products Administration, which approved the withdrawal of its drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) [1] - Pegylated Interferon α-2 Injection is a novel long-acting interferon developed by Kaiyin Technology, which was approved in 2018 for the treatment of adult chronic hepatitis C [1]

Group 1 - The core view of the report is that Zai Lab (02509) is expected to have EPS of 1.61, 0.88, and 0.55 RMB for the years 2025 to 2027, respectively, with a target price of 33.0 HKD, indicating a 41.6% upside potential from the current stock price [1] - The company has established a comprehensive end-to-end innovative drug development system, focusing on autoimmune and allergic diseases, with a pipeline covering four major therapeutic areas [2] - Zai Lab has one approved product and ten products in the research phase, with over 20 IND approvals, indicating a strong pipeline and development capability [2] Group 2 - The company has rapidly iterated its dual-antibody products in the autoimmune field, achieving three overseas collaborations within the year, demonstrating recognition from multinational corporations and biotech firms [3] - Potential catalysts for growth include the readout of Phase III data for QX005N, BLA submissions for QX002N, and the initiation of clinical trials for dual-antibody products both domestically and internationally [3]

Core Viewpoint - The company has withdrawn its drug registration application for the hepatitis B treatment, leading to a significant drop in its stock price, indicating investor concerns about the future of its drug development pipeline [1][2][3] Group 1: Drug Development and Regulatory Actions - The drug in question, Peginterferon α-2a injection, was the fastest progressing hepatitis B drug in the company's pipeline and had recently reached the application stage for market approval [1] - The company received a termination notice from the National Medical Products Administration, agreeing to the withdrawal of the drug registration application for the hepatitis B indication [1][2] - The company plans to supplement clinical case studies as per regulatory requirements and may resubmit the registration application in the future [2][3] Group 2: Financial Impact and Market Reaction - The withdrawal of the registration application resulted in an 11.78% drop in the company's stock price, making it the largest decline in the A-share market on that day [1] - The company has fully recognized impairment losses related to the development expenses of the Peginterferon α-2a injection project, which will reduce its profit by 111 million yuan in 2025 [3] - This decision has raised concerns among investors about the viability of the drug's development for hepatitis B, although the company maintains that it has not abandoned the project [3] Group 3: Industry Context - Hepatitis B virus infection is a significant global public health issue, with chronic hepatitis B potentially leading to severe complications like cirrhosis and liver cancer if not properly managed [2] - The company has previously achieved a high cure rate for hepatitis C with its all-oral drug series, but faces increasing competition in the hepatitis C market, prompting a shift towards innovative hepatitis B treatments [2]

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the **Chinese technology industry**, highlighting its significant competitiveness in areas such as brain-computer integration, biomanufacturing, and commercial aviation, which have attracted substantial investment and become market highlights [1][2]. Core Insights and Arguments - **Market Trends**: The Chinese market's upward trend in 2026 has exceeded expectations, driven by three main factors: technological advancements, ample liquidity, and an improved geopolitical risk appetite [2]. - **Investment in AI**: China is investing approximately **4 trillion to 5 trillion RMB** in AI computing centers, while the U.S. has invested between **$500 billion to $600 billion** in the same area. Despite some shortcomings in computing power, China has advantages in lightweight models and commercial applications [3]. - **Biopharmaceuticals**: By 2035, it is projected that nearly **20%** of new innovative drugs approved by the U.S. FDA will come from China, increasing to over **33%** by 2040 [4]. - **Response to International Perception**: China is leveraging its strong industrial chain advantages to counteract the conservative or pessimistic views of the international community, particularly in AI and traditional industries [5]. - **Impact of AI on Employment**: AI is expected to significantly impact productivity and the job market, with studies suggesting that **80%** of jobs may be affected, and **40%** could be replaced by AI. Caution is advised regarding the social implications of these changes [6]. - **Global Market Share**: Chinese enterprises currently hold **15%** of the global export market share, with expectations to increase to around **17%** in the next five years, driven by innovation and supply chain optimization [7]. Additional Important Insights - **Economic Transition Challenges**: Relying solely on technological advancements is insufficient for addressing domestic economic transformation issues. Attention must also be given to traditional industry adjustments and real estate market pressures [7]. - **Dollar Asset Perception**: There has been a shift in global sovereign asset investors' views on the dollar, although it is not expected to collapse. The trust in the dollar is declining, leading to increased importance of other strategic assets [8][9]. - **Renminbi Appreciation**: The recent appreciation of the Renminbi is attributed to the dollar's depreciation and seasonal factors. However, long-term appreciation may not be beneficial due to ongoing economic challenges [10]. - **Trends in Domestic Asset Allocation**: There has been a significant inflow of funds into the capital market, with equity and mixed funds increasing by approximately **2 trillion RMB** [11][12]. - **Real Estate Market Stabilization**: To stabilize the real estate market, policy reforms such as mortgage rate adjustments are suggested, drawing on successful experiences from regions like Hong Kong [13]. - **Social Security and Consumption**: The inadequacy of the social security system contributes to high savings rates. Improving social security benefits could enhance consumer spending potential [14]. - **Outlook for 2026**: The outlook for 2026 includes technological highlights, liquidity, and improved risk appetite, but there remains a gap between these factors and corporate profit improvements. Long-term sustainable development will depend on stabilizing the real estate market and reforming the social security system [15].

Core Viewpoint - CICC has initiated coverage on Zai Lab (02509) with an outperform rating, projecting EPS of 1.61, 0.88, and 0.55 CNY for 2025-2027, respectively, and a target price of HKD 33.0, indicating a 41.6% upside from the current stock price [1] Group 1: Company Overview - Zai Lab, established in 2015, is one of the few domestic biotech companies focused on the research and development of autoimmune and allergic diseases, having built an end-to-end innovative drug development system from early research to commercialization [2] - The company has developed a comprehensive R&D pipeline covering four major therapeutic areas: dermatology, rheumatology, respiratory, and gastroenterology, with one approved product, ten products in development, and over twenty IND approvals [2] Group 2: Product Development and Partnerships - Zai Lab has efficiently developed a series of long-acting bispecific antibodies (bsAbs) in the autoimmune field, with significant overseas licensing agreements for products QX030N, QX031N, and QX027N, indicating recognition from multinational corporations and investment institutions [3] - Potential catalysts for growth include the Phase III data readout and BLA submission for QX005N, BLA submission for QX002N, and the gradual initiation of domestic and overseas clinical trials for bispecific products [3]

消息面上，英矽智能近日发布公告称，与衡泰生物就ISM8969项目达成共同开发合作协议。基于这一独 家战略伙伴关系，双方将共同加速推进ISM8969的全球开发，这是一款口服且具备穿透血脑屏障性质的 新型NLRP3抑制剂，拟用于中枢神经系统疾病治疗。 根据协议条款，英矽智能将授予衡泰生物对ISM8969在全球范围内进行研究、开发、注册、生产和商业 化的50%权利。与此同时，英矽智能有权获得逾5亿港币的预付款及里程碑付款，包括一笔预计将在协 议生效日起30日内支付的7800万港币预付款。 （原标题：港股异动 | 英矽智能(03696)早盘涨近5% 公司携手衡泰生物共同开发新型NLRP3抑制剂） 智通财经APP获悉，英矽智能(03696)早盘涨近5%，截至发稿，涨3.68%，报55港元，成交额2152.11万 港元。 ...

凯因科技对培集成干扰素α-2注射液（新增乙肝适应证）项目涉及的相关开发支出全额计提资产减值准 备，相应减少2025年度利润总额约1.11亿元。 2025年前三季度，凯因科技营业收入为9.27亿元，利润总额为1.31亿元。此次撤回药品注册申请预计将 对凯因科技2025年全年业绩产生较大影响。中经记者 晏国文 卢志坤 北京报道 【凯因科技撤回一药品注册申请 2025年利润减少1.11亿元】2026年1月20日，科创板上市公司凯因科技 （688687.SH）披露，撤回培集成干扰素α-2注射液（新增乙肝适应证）的药品注册申请。 培集成干扰素α-2注射液是一款已上市药品，适用于治疗成人慢性丙型肝炎（HCV），于2018年获得药 品注册批件和新药证书。 2024年9月，凯因科技对该药品新增申报适应证。此次撤回申请的是新增申报适应证。 凯因科技方面表示，根据国家药监局最新审评建议，经审慎研究，公司决定主动撤回本次药品注册申 请，并将根据国家药监局的有关要求，进一步补充临床病例研究，根据情况再次提交注册申请。 ...

Core Viewpoint - The company BaiO Saite-B (02315) has seen a nearly 7% increase in stock price, attributed to the completion of the localization of its AI-driven antibody drug research platform, which enhances its core business collaboration with the QianShu WanKang program [1] Group 1 - BaiO Saite-B's stock price rose by 5.08% to HKD 39.72, with a trading volume of HKD 28.32 million [1] - The company announced the successful localization of its AI-driven antibody drug research platform, which is now fully integrated with its core business initiatives [1] - The ongoing integration of the QianShu WanKang program with the AI system is expected to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library [1] Group 2 - The advancements in AI localization are aimed at improving the research efficiency of preclinical PCC molecules for pharmaceutical partners [1] - This development is anticipated to propel the antibody discovery business into a new phase of growth [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant increase in stock price, rising nearly 7% and currently trading at 39.72 HKD, with a transaction volume of 28.32 million HKD. The company has completed the localization of its AI-driven antibody drug development platform, enhancing synergy with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1]. Group 1 - The company has successfully localized its AI-driven antibody drug development platform [1]. - The integration of the AI system with the "Thousand Mice and Ten Thousand Antibodies" plan is ongoing, which is expected to provide more efficient research tools and a richer antibody molecule library for global pharmaceutical companies [1]. - This development aims to improve the efficiency of preclinical PCC molecule research for pharmaceutical partners, marking a new phase in the antibody discovery business [1].